It has been an explosive twenty-four hours in the biotech-verse, as analysts are prompted to offer insights on Sarepta Therapeutics Inc (NASDAQ:SRPT), with shares shooting …
After a long regulatory process filled with delays and intense speculation, the FDA finally approved Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Exondys 51 (eteplirsen) for the …
Sarepta Therapeutics Inc After a long regulatory process filled with delays and intense speculation, FDA approved Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Exondys 51 (eteplirsen) for …
Sarepta Therapeutics Inc (NASDAQ:SRPT) investors have a reason to cheer following the news that the FDA today approved Exondys 51 (eteplirsen), the Company’s lead drug candidate …
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that the FDA has granted accelerated approval for EXONDYS 51™ (eteplirsen) as a once weekly intravenous infusion of 30 milligrams per …
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are down nearly 3% to $31.40 in pre-market trading, following a statement from Jefferies’ key opinion leader (KOL) regarding yesterday’s …
In a research note issued Wednesday, JMP Securities analyst Liisa Bayko reiterated an Underperform rating on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) with a $10 …
Biotech stocks are looking to erase their losses over the past month today, as the iShares Nasdaq Biotechnology ETF (IBB) gained nearly 2%. Among the equities in …
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares shot up nearly 13% today in the wake of Dr. Ronald Farkas, arguably the most oppositional team leader …
Cowen analyst Ritu Baral provides insight on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) after the biotech company recently posted second-quarter results and offered …
